Cargando…
A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer
BACKGROUND: Cell division cycle 6 (cdc6) is a key factor of DNA replication initiation license system and a proto‐oncogene. It has been detected in some tumor tissues to aid cancer diagnosis in many research projects. However, it remains unclear that if cdc6 could be detected in the peripheral blood...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307357/ https://www.ncbi.nlm.nih.gov/pubmed/32249466 http://dx.doi.org/10.1002/jcla.23245 |
_version_ | 1783548793428377600 |
---|---|
author | An, Cheng Liu, Guijian Cheng, Shi Pang, Bo Sun, Shipeng Zhang, Yaying Pan, Zhongdai Kang, Xixiong |
author_facet | An, Cheng Liu, Guijian Cheng, Shi Pang, Bo Sun, Shipeng Zhang, Yaying Pan, Zhongdai Kang, Xixiong |
author_sort | An, Cheng |
collection | PubMed |
description | BACKGROUND: Cell division cycle 6 (cdc6) is a key factor of DNA replication initiation license system and a proto‐oncogene. It has been detected in some tumor tissues to aid cancer diagnosis in many research projects. However, it remains unclear that if cdc6 could be detected in the peripheral blood, just like liquid biopsy, in solid tumor patients. The aim of this study is to investigate the possibility of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer. METHODS: We first detected the expression of cdc6 in peripheral blood mononuclear cells (PBMCs) and tumor cells by in situ hybridization with cdc6 RNA probe. Then, we examined the expression of cdc6 in PBMCs from health individual, mononuclear cells from cord blood, or A549 cell line by RT‐qPCR. Furthermore, we used RT‐qPCR to test the cdc6 expression in PBMCs from tumor patients (test group) and non‐tumor individuals as a control group. Chi‐square test with Fisher's exact test was used to analyze the statistical significance of the difference. P < .05 is considered as statistically significant difference. RESULTS: When compared the cdc6 expression in cells from difference sources, we found that A549 tumor cell line had the strongest expression of cdc6, samples from cord blood showed the least expression level, indicating the detection strategy of RT‐qPCR is reasonable. Using this method, we studied whether cdc6 in Peripheral blood could be detected as a biomarker by examining cdc6 expression from PBMCs of patients with lung cancer. We found 20% of patients with lung cancer were cdc6 positive in PBMCs, whereas only 4.26% was found positive in the control group (P = .039, P < .05). CONCLUSION: Cell division cycle 6 has a potential to be used as a circulating tumor cell biomarker for lung cancer. Further study in clinical application is still broad needed. |
format | Online Article Text |
id | pubmed-7307357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73073572020-06-23 A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer An, Cheng Liu, Guijian Cheng, Shi Pang, Bo Sun, Shipeng Zhang, Yaying Pan, Zhongdai Kang, Xixiong J Clin Lab Anal Research Articles BACKGROUND: Cell division cycle 6 (cdc6) is a key factor of DNA replication initiation license system and a proto‐oncogene. It has been detected in some tumor tissues to aid cancer diagnosis in many research projects. However, it remains unclear that if cdc6 could be detected in the peripheral blood, just like liquid biopsy, in solid tumor patients. The aim of this study is to investigate the possibility of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer. METHODS: We first detected the expression of cdc6 in peripheral blood mononuclear cells (PBMCs) and tumor cells by in situ hybridization with cdc6 RNA probe. Then, we examined the expression of cdc6 in PBMCs from health individual, mononuclear cells from cord blood, or A549 cell line by RT‐qPCR. Furthermore, we used RT‐qPCR to test the cdc6 expression in PBMCs from tumor patients (test group) and non‐tumor individuals as a control group. Chi‐square test with Fisher's exact test was used to analyze the statistical significance of the difference. P < .05 is considered as statistically significant difference. RESULTS: When compared the cdc6 expression in cells from difference sources, we found that A549 tumor cell line had the strongest expression of cdc6, samples from cord blood showed the least expression level, indicating the detection strategy of RT‐qPCR is reasonable. Using this method, we studied whether cdc6 in Peripheral blood could be detected as a biomarker by examining cdc6 expression from PBMCs of patients with lung cancer. We found 20% of patients with lung cancer were cdc6 positive in PBMCs, whereas only 4.26% was found positive in the control group (P = .039, P < .05). CONCLUSION: Cell division cycle 6 has a potential to be used as a circulating tumor cell biomarker for lung cancer. Further study in clinical application is still broad needed. John Wiley and Sons Inc. 2020-04-06 /pmc/articles/PMC7307357/ /pubmed/32249466 http://dx.doi.org/10.1002/jcla.23245 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles An, Cheng Liu, Guijian Cheng, Shi Pang, Bo Sun, Shipeng Zhang, Yaying Pan, Zhongdai Kang, Xixiong A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer |
title | A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer |
title_full | A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer |
title_fullStr | A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer |
title_full_unstemmed | A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer |
title_short | A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer |
title_sort | pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307357/ https://www.ncbi.nlm.nih.gov/pubmed/32249466 http://dx.doi.org/10.1002/jcla.23245 |
work_keys_str_mv | AT ancheng apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT liuguijian apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT chengshi apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT pangbo apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT sunshipeng apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT zhangyaying apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT panzhongdai apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT kangxixiong apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT ancheng pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT liuguijian pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT chengshi pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT pangbo pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT sunshipeng pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT zhangyaying pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT panzhongdai pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer AT kangxixiong pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer |